Angel Pharmaceuticals

About Angel Pharmaceuticals

Angel Pharmaceuticals is a clinical-stage biopharmaceutical company established in 2020, focused on developing and commercializing a pipeline of targeted investigational medicines for cancer, autoimmune, and infectious diseases, primarily within Greater China. The company was co-founded by U.S.-based Corvus Pharmaceuticals (NASDAQ: CRVS) and a consortium of Chinese investors, including Puissance Capital, Hisun Pharmaceuticals, and Tigermed. This strategic collaboration enables the clinical development and commercialization of Corvus's drug pipeline in China. Angel Pharmaceuticals is headquartered in Jiaxing, China, with research and development facilities in both Jiaxing and Burlingame, California. The business model centers on in-licensing and advancing clinical-stage candidates. Angel licensed the rights from Corvus to develop and commercialize three assets in greater China: soquelitinib (an ITK inhibitor), ciforadenant (an adenosine A2A receptor antagonist), and mupadolimab (a monoclonal antibody targeting CD73). The company also obtained global rights to Corvus's preclinical BTK inhibitor programs. Corvus is the largest shareholder, holding a significant equity stake. One of Corvus's co-founders, Dr. Richard A. Miller, who previously co-founded IDEC (leading to the development of rituximab) and Pharmacyclics (known for ibrutinib), serves on Angel Pharmaceuticals' board. The company's lead asset, soquelitinib, is an oral small molecule designed to selectively inhibit ITK (interleukin-2-inducible T-cell kinase), an enzyme crucial for T-cell function. Angel is advancing soquelitinib in multiple trials in China, including a Phase 1b/2 trial for atopic dermatitis and a planned Phase 2 trial for asthma, with initial data from the dermatitis trial expected in late 2026. Other pipeline candidates include ciforadenant, being studied for renal cell carcinoma, and mupadolimab for solid tumors like non-small cell lung cancer. The company aims to make these innovative drugs more accessible to patients in the region. Keywords: biopharmaceutical, drug development, China, oncology, autoimmune diseases, ITK inhibitor, soquelitinib, ciforadenant, mupadolimab, Corvus Pharmaceuticals, clinical trials, T-cell lymphoma, atopic dermatitis, asthma, adenosine A2A receptor, CD73 antibody, BTK inhibitor, cancer therapy, immunology, targeted therapy, Jiaxing, small molecules, monoclonal antibodies, clinical-stage